139 related articles for article (PubMed ID: 8398707)
1. Phase I and pharmacologic study of irinotecan in combination with cisplatin for advanced lung cancer.
Masuda N; Fukuoka M; Kudoh S; Kusunoki Y; Matsui K; Takifuji N; Nakagawa K; Tamanoi M; Nitta T; Hirashima T
Br J Cancer; 1993 Oct; 68(4):777-82. PubMed ID: 8398707
[TBL] [Abstract][Full Text] [Related]
2. Phase I and pharmacologic study of irinotecan and etoposide with recombinant human granulocyte colony-stimulating factor support for advanced lung cancer.
Masuda N; Fukuoka M; Kudoh S; Matsui K; Kusunoki Y; Takada M; Nakagawa K; Hirashima T; Tsukada H; Yana T
J Clin Oncol; 1994 Sep; 12(9):1833-41. PubMed ID: 7521905
[TBL] [Abstract][Full Text] [Related]
3. Relationship between the pharmacokinetics of irinotecan and diarrhea during combination chemotherapy with cisplatin.
Kudoh S; Fukuoka M; Masuda N; Yoshikawa A; Kusunoki Y; Matsui K; Negoro S; Takifuji N; Nakagawa K; Hirashima T
Jpn J Cancer Res; 1995 Apr; 86(4):406-13. PubMed ID: 7775263
[TBL] [Abstract][Full Text] [Related]
4. Phase I study of irinotecan and cisplatin with granulocyte colony-stimulating factor support for advanced non-small-cell lung cancer.
Masuda N; Fukuoka M; Kudoh S; Kusunoki Y; Matsui K; Nakagawa K; Hirashima T; Tamanoi M; Nitta T; Yana T
J Clin Oncol; 1994 Jan; 12(1):90-6. PubMed ID: 7505810
[TBL] [Abstract][Full Text] [Related]
5. Fractionated administration of irinotecan and cisplatin for treatment of lung cancer: a phase I study.
Ueoka H; Tabata M; Kiura K; Shibayama T; Gemba K; Segawa Y; Chikamori K; Yonei T; Hiraki S; Harada M
Br J Cancer; 1999 Feb; 79(5-6):984-90. PubMed ID: 10070901
[TBL] [Abstract][Full Text] [Related]
6. Phase I clinical trial of irinotecan (CPT-11), 7-ethyl-10-[4-(1-piperidino)-1-piperidino]carbonyloxy-camptothecin, and cisplatin in combination with fixed dose of vindesine in advanced non-small cell lung cancer.
Shinkai T; Arioka H; Kunikane H; Eguchi K; Sasaki Y; Tamura T; Ohe Y; Oshita F; Nishio M; Karato A
Cancer Res; 1994 May; 54(10):2636-42. PubMed ID: 8168091
[TBL] [Abstract][Full Text] [Related]
7. Phase I and pharmacokinetic study of irinotecan (CPT-11) administered daily for three consecutive days every three weeks in patients with advanced solid tumors.
Catimel G; Chabot GG; Guastalla JP; Dumortier A; Cote C; Engel C; Gouyette A; Mathieu-Boué A; Mahjoubi M; Clavel M
Ann Oncol; 1995 Feb; 6(2):133-40. PubMed ID: 7786821
[TBL] [Abstract][Full Text] [Related]
8. Phase I-II study of irinotecan hydrochloride combined with cisplatin in patients with advanced gastric cancer.
Shirao K; Shimada Y; Kondo H; Saito D; Yamao T; Ono H; Yokoyama T; Fukuda H; Oka M; Watanabe Y; Ohtsu A; Boku N; Fujii T; Oda Y; Muro K; Yoshida S
J Clin Oncol; 1997 Mar; 15(3):921-7. PubMed ID: 9060529
[TBL] [Abstract][Full Text] [Related]
9. Phase I and pharmacologic studies of the camptothecin analog irinotecan administered every 3 weeks in cancer patients.
Abigerges D; Chabot GG; Armand JP; Hérait P; Gouyette A; Gandia D
J Clin Oncol; 1995 Jan; 13(1):210-21. PubMed ID: 7799022
[TBL] [Abstract][Full Text] [Related]
10. Phase II study of irinotecan plus cisplatin in patients with advanced non-small-cell lung cancer.
DeVore RF; Johnson DH; Crawford J; Garst J; Dimery IW; Eckardt J; Eckhardt SG; Elfring GL; Schaaf LJ; Hanover CK; Miller LL
J Clin Oncol; 1999 Sep; 17(9):2710-20. PubMed ID: 10561345
[TBL] [Abstract][Full Text] [Related]
11. Phase I study of weekly CPT-11 (irinotecan)/docetaxel in patients with advanced solid tumors.
Font A; Sanchez JM; Rosell R; Taron M; Martinez E; Guillot M; Manzano JL; Margeli M; Barnadas A; Abad A
Lung Cancer; 2002 Aug; 37(2):213-8. PubMed ID: 12140145
[TBL] [Abstract][Full Text] [Related]
12. Irinotecan (CPT-11) in combination with weekly administration of cisplatin (CDDP) for non-small-cell lung cancer.
Kobayashi K; Shinbara A; Kamimura M; Takeda Y; Kudo K; Kabe J; Hibino S; Hino M; Shibuya M; Kudoh S
Cancer Chemother Pharmacol; 1998; 42(1):53-8. PubMed ID: 9619758
[TBL] [Abstract][Full Text] [Related]
13. Weekly irinotecan and cisplatin in advanced non-small cell lung cancer: a multicenter phase II study.
Jagasia MH; Langer CJ; Johnson DH; Yunus F; Rodgers JS; Schlabach LL; Cohen AG; Shyr Y; Carbone DP; Devore RF
Clin Cancer Res; 2001 Jan; 7(1):68-73. PubMed ID: 11205920
[TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetic study of two infusion schedules of irinotecan combined with cisplatin in patients with advanced gastric cancer.
Fujitani K; Tsujinaka T; Hirao M
Oncology; 2003; 64(2):111-5. PubMed ID: 12566907
[TBL] [Abstract][Full Text] [Related]
15. Clinical studies of irinotecan alone and in combination with cisplatin.
Fukuoka M; Masuda N
Cancer Chemother Pharmacol; 1994; 34 Suppl():S105-11. PubMed ID: 8070018
[TBL] [Abstract][Full Text] [Related]
16. Phase I trial of the combination of irinotecan, paclitaxel, and carboplatin in patients with advanced non-small-cell lung cancer.
Socinski MA; Sandler AB; Miller LL; Locker PK; Hanover CK; Elfring GL; Israel VK; Pirotta N; Natale RB
J Clin Oncol; 2001 Feb; 19(4):1078-87. PubMed ID: 11181672
[TBL] [Abstract][Full Text] [Related]
17. A phase II trial of combination of CPT-11 and cisplatin for advanced non-small-cell lung cancer. CPT-11 Lung Cancer Study Group.
Masuda N; Fukuoka M; Fujita A; Kurita Y; Tsuchiya S; Nagao K; Negoro S; Nishikawa H; Katakami N; Nakagawa K; Niitani H
Br J Cancer; 1998 Jul; 78(2):251-6. PubMed ID: 9683302
[TBL] [Abstract][Full Text] [Related]
18. Phase I and pharmacologic study of irinotecan and amrubicin in advanced non-small cell lung cancer.
Yanaihara T; Yokoba M; Onoda S; Yamamoto M; Ryuge S; Hagiri S; Katagiri M; Wada M; Mitsufuji H; Kubota M; Arai S; Kobayashi H; Yanase N; Abe T; Masuda N
Cancer Chemother Pharmacol; 2007 Mar; 59(4):419-27. PubMed ID: 16832665
[TBL] [Abstract][Full Text] [Related]
19. Dose-finding study of irinotecan and cisplatin plus concurrent radiotherapy for unresectable stage III non-small-cell lung cancer [seecomments].
Yokoyama A; Kurita Y; Saijo N; Tamura T; Noda K; Shimokata K; Matsuda T
Br J Cancer; 1998 Jul; 78(2):257-62. PubMed ID: 9683303
[TBL] [Abstract][Full Text] [Related]
20. Biweekly docetaxel-irinotecan with filgrastim support in pretreated breast and non-small-cell lung cancer patients. A phase I study.
Frasci G; Comella P; Thomas R; Di Bonito M; Lapenta L; Capasso I; Botti G; Vallone P; De Rosa V; D'Aiuto G; Comella G
Cancer Chemother Pharmacol; 2004 Jan; 53(1):25-32. PubMed ID: 14513281
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
